Hyperglycemia drug developer raises $25 million to advance pipeline

A biotechnology company developing a long-acting drug and insulin to treat hyperglycemia in people with type 1 and type 2 diabetes, and a treatment for hypertension has raised $25 million in a series B financing round. The investment for the Malvern, Pennsylvania-based PhaseBio Pharmaceuticals came from established investors that include Johnson & Johnson Development Corporation, […]


Hyperglycemia drug gets positive results in clinical trial

PhaseBio Pharmaceuticals‘ phase I/IIa clinical study for its drug, Glymera, for the treatment of hyperglycemia in patients with type 2 diabetes, met with positive results, according to a release from the company. The single and multiple ascending dose study of 80 subjects in three U.S. study centers assessed the safety, tolerability and pharmacokinetic or PK […]